Outcomes in patients with lung cancer treated with crizotinib and erlotinib in routine clinical practice: A post‐authorization safety cohort study conducted in Europe and …

V Ehrenstein, K Huang, J Kahlert… - … and Drug Safety, 2021 - Wiley Online Library
Purpose We examined safety outcomes of interest (SOI) and overall survival (OS) among
lung cancer patients initiating crizotinib and erlotinib in routine clinical practice. Methods …
被引用次数：7 相关文章

Outcomes in patients with lung cancer treated with crizotinib and erlotinib in routine clinical practice: A post-authorization safety cohort study conducted in Europe and …

V Ehrenstein, K Huang, J Kahlert… - … and Drug Safety, 2021 - pure.au.dk
Purpose: We examined safety outcomes of interest (SOI) and overall survival (OS) among
lung cancer patients initiating crizotinib and erlotinib in routine clinical practice. Methods …

Outcomes in patients with lung cancer treated with crizotinib and erlotinib in routine clinical practice: A post-authorization safety cohort study conducted in Europe and …

V Ehrenstein, K Huang, J Kahlert… - … and Drug Safety, 2021 - europepmc.org
Purpose We examined safety outcomes of interest (SOI) and overall survival (OS) among
lung cancer patients initiating crizotinib and erlotinib in routine clinical practice. Methods …

Outcomes in patients with lung cancer treated with crizotinib and erlotinib in routine clinical practice: A post-authorization safety cohort study conducted in Europe and …

V Ehrenstein, K Huang, J Kahlert… - … and drug safety, 2021 - pubmed.ncbi.nlm.nih.gov
Purpose We examined safety outcomes of interest (SOI) and overall survival (OS) among
lung cancer patients initiating crizotinib and erlotinib in routine clinical practice. Methods …